SCHEMBL2320356

SCHEMBL2320356

O=C(O)c1ccc(N[C@H]2CCc3cc4nc(COCc5ccccc5)[nH]c(=O)c4cc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.42
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE5A O76074 1/20 0.39
KDM4E B2RXH2 1/20 0.38
RECQL P46063 1/20 0.38
TNKS O95271 3/20 0.37
TNKS2 Q9H2K2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PARP14 Q460N5 3/20 0.37
LIPG Q9Y5X9 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
PDE9A O76083 1/20 0.36
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2320352 1.00 PARP1 (0.42) PARP1TSHRSMN1; SMN2PDE5AKDM4E
SCHEMBL2319459 0.90 PARP1 (0.38) PARP1TSHRSMN1; SMN2TNKSTNKS2
SCHEMBL2319454 0.90 PARP1 (0.38) PARP1TSHRSMN1; SMN2TNKSTNKS2
SCHEMBL15958208 0.90 KDM4E (0.39) PARP1TSHRSMN1; SMN2KDM4EALDH1A1
SCHEMBL1038155 0.88 PARP1 (0.40) PARP1TSHRSMN1; SMN2PDE5AKDM4E
SCHEMBL1544255 0.88 PARP1 (0.40) PARP1TSHRSMN1; SMN2PDE5AKDM4E
SCHEMBL1343569 0.88 PARP1 (0.40) PARP1TSHRSMN1; SMN2PDE5AKDM4E
SCHEMBL15958508 0.88 MAPT (0.37) PARP1TSHRSMN1; SMN2TNKSTNKS2
SCHEMBL3674775 0.86 KDM4E (0.43) PARP1TSHRPDE5AKDM4ERECQL
SCHEMBL3674777 0.86 KDM4E (0.43) PARP1TSHRPDE5AKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2213664-B1 PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES BTG INT LTD (GB) 2014-04-30 EP disclosed
EP-1421069-B1 PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES BTG INT LTD (GB) 2011-08-10 EP disclosed
EP-2213664-A1 PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES BTG International Limited (GB) 2010-08-04 EP disclosed
US-7250511-B2 Process for the preparation of cyclopenta[g]quinazoline derivatives BTG INTERNATIONAL LIMITED (GB) 2007-07-31 US disclosed
US-20040266798-A1 Process for the preparation of cyclopenta[g]quinazoline derivatives BTG INTERNATIONAL LIMITED (GB) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266798-A1 Process for the preparation of cyclopenta[g]quinazoline derivatives COX6A1, MT-ND6, CYP2D6 PARP1 745/4885TSHR 4467/4885SMN1; SMN2 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.